Comparison
Liraglutide vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
204656-20-2
2179963-22-7
Molecular weight
3751 g/mol
4727 g/mol
Half-life
13 h
168 h
Sequence
HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRGmodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Liraglutide
Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
2
of which in humans
4
2
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
1
2